WS
GSK icon

Wedbush Securities’s GSK GSK Stock Holding History

Wedbush Securities’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404K Sell
7,318
-421
-5% -$22.8K 0.01% 757
2025
Q4 		$380K Buy
7,739
+572
+8% +$26.7K 0.01% 777
2025
Q3 		$309K Buy
7,167
+1,046
+17% +$40.9K 0.01% 835
2025
Q2 		$235K Buy
6,121
+696
+13% +$26.6K 0.01% 963
2025
Q1 		$210K Buy
+5,425
New +$199K 0.01% 990
2024
Q3 		– Sell
-10,541
Closed -$406K – 1168
2024
Q2 		$406K Sell
10,541
-1,627
-13% -$68.4K 0.01% 710
2024
Q1 		$522K Sell
12,168
-7,406
-38% -$305K 0.02% 624
2023
Q4 		$725K Sell
19,574
-6
-0% -$215 0.03% 424
2023
Q3 		$710K Sell
19,580
-1,368
-7% -$48.6K 0.04% 404
2023
Q2 		$747K Sell
20,948
-413
-2% -$14.8K 0.04% 403
2023
Q1 		$760K Buy
21,361
+20
+0.1% +$700 0.04% 402
2022
Q4 		$750K Sell
21,341
-2,558
-11% -$85.2K 0.04% 382
2022
Q3 		$703K Buy
23,899
+12,741
+114% +$483K 0.04% 393
2022
Q2 		$607K Sell
11,158
-703
-6% -$38.8K 0.03% 454
2022
Q1 		$646K Sell
11,861
-435
-4% -$23.6K 0.03% 485
2021
Q4 		$678K Buy
12,296
+178
+1% +$9.26K 0.03% 509
2021
Q3 		$579K Sell
12,118
-9,538
-44% -$479K 0.03% 545
2021
Q2 		$1.08M Buy
21,656
+2,735
+14% +$131K 0.05% 340
2021
Q1 		$844K Sell
18,921
-11,353
-38% -$515K 0.05% 381
2020
Q4 		$1.39M Sell
30,274
-4,284
-12% -$197K 0.12% 182
2020
Q3 		$1.63M Sell
34,558
-1,135
-3% -$56.9K 0.16% 138
2020
Q2 		$1.82M Sell
35,693
-1,889
-5% -$96.9K 0.17% 129
2020
Q1 		$1.78M Sell
37,582
-3,311
-8% -$177K 0.21% 108
2019
Q4 		$2.4M Sell
40,893
-1,009
-2% -$56.1K 0.21% 100
2019
Q3 		$2.23M Sell
41,902
-1,430
-3% -$73.6K 0.22% 99
2019
Q2 		$2.17M Buy
43,332
+5,154
+13% +$259K 0.22% 101
2019
Q1 		$1.99M Buy
38,178
+1,436
+4% +$71.8K 0.21% 109
2018
Q4 		$1.75M Sell
36,742
-1,546
-4% -$76.1K 0.22% 108
2018
Q3 		$1.92M Sell
38,288
-206
-0.5% -$10.5K 0.22% 97
2018
Q2 		$1.94M Sell
38,494
-105
-0.3% -$5.29K 0.24% 84
2018
Q1 		$1.89M Buy
38,599
+16,371
+74% +$762K 0.25% 90
2017
Q4 		$986K Sell
22,228
-3,370
-13% -$156K 0.12% 205
2017
Q3 		$1.3M Sell
25,598
-7,728
-23% -$392K 0.17% 128
2017
Q2 		$1.8M Buy
33,326
+7,879
+31% +$420K 0.23% 89
2017
Q1 		$1.34M Buy
25,447
+821
+3% +$41.6K 0.18% 117
2016
Q4 		$1.19M Buy
24,626
+2,092
+9% +$103K 0.17% 128
2016
Q3 		$1.22M Buy
22,534
+2,815
+14% +$154K 0.18% 119
2016
Q2 		$1.07M Buy
19,719
+1,904
+11% +$100K 0.17% 125
2016
Q1 		$903K Buy
17,815
+972
+6% +$48.4K 0.16% 143
2015
Q4 		$850K Buy
16,843
+1,052
+7% +$53.6K 0.15% 142
2015
Q3 		$759K Sell
15,791
-1,430
-8% -$74.4K 0.15% 156
2015
Q2 		$897K Buy
17,221
+3,005
+21% +$169K 0.17% 144
2015
Q1 		$820K Sell
14,216
-1,062
-7% -$60.9K 0.14% 166
2014
Q4 		$816K Sell
15,278
-95
-0.6% -$5.32K 0.13% 160
2014
Q3 		$883K Buy
15,373
+2,693
+21% +$165K 0.14% 143
2014
Q2 		$848K Buy
12,680
+2,024
+19% +$137K 0.14% 148
2014
Q1 		$712K Buy
10,656
+1,512
+17% +$102K 0.12% 173
2013
Q4 		$610K Sell
9,144
-1,039
-10% -$67.4K 0.14% 168
2013
Q3 		$639K Sell
10,183
-2,556
-20% -$165K 0.17% 147
2013
Q2 		$796K Buy
+12,739
New +$809K 0.22% 117

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wedbush Securities's GSK Position: Q1 2026 in Review

Wedbush Securities reduced its GSK (GSK) stake by 5.4% in Q1 2026, selling an estimated $22.8K and leaving 7,318 shares worth $404K. The position accounts for 0.01% of the portfolio, ranked #757.

Wedbush Securities first reported a position in GSK in Q2 2013 and has held it in 50 quarters since. The position peaked at $2.4M in Q4 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Wedbush Securities held 7,318 shares of GSK worth $404K as of Q1 2026.
  • Wedbush Securities sold 421 GSK shares in Q1 2026, an estimated $22.8K.
  • GSK made up 0.01% of Wedbush Securities's portfolio in Q1 2026, its #757 holding.
  • Wedbush Securities first reported a position in GSK in Q2 2013 and has held it in 50 quarters since.
  • Wedbush Securities's GSK position peaked at $2.4M in Q4 2019.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.